Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NGFR expression predicts tumor recurrence in radiotherapy/chemoradiotherapy-treated HPV-negative pharyngeal squamous cell carcinoma

  • García-Agulló, Juan
  • Santos, Vanesa
  • Garcia-Mayea, Yoelsis
  • de Luxan-Delgado, Beatriz
  • Bataller, Marina
  • Lleonart, Matilde Esther
  • Rodrigo, Juan P
  • García-Pedrero, Juana M
  • Álvarez-Fernández, Mónica
  • Peinado, Héctor
Supplementary data to this article can be found online at https://doi.org/10.1016/j.oraloncology.2026.108080, Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with high mortality rates, often exhibiting resistance to conventional treatments such as radiotherapy (RT) or a combination of chemotherapy and radiotherapy (CRT). The nerve growth factor receptor (NGFR, also known as p75NTR or CD271) is a well-established cancer stem cell marker in melanoma, where it has been linked to resistance to multiple therapies. In HNSCC, NGFR has been reported as a poor prognostic marker, with its overexpression associated with disease progression. However, its contribution to therapy resistance in HNSCC remains unknown., Research in the laboratory of Dr Peinado is supported by grants from Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación / State Research Agencia Financiadora (AEI − Ministry of Science and Innovation: PID2020-118558RB-I00 (MICIU/AEI/https://doi.org/10.13039/501100011033), RETOS SAF2017-82924-R (AEI/https://doi.org/10.13039/501100011033/FEDER-UE), PDC2021-121102-I00 (MCIN/AEI/https://doi.org/10.13039/501100011033, European Union “NextGenerationEU”/PRTR), PID2023-147503OB-I00 funded by MCIU/AEI /https://doi.org/10.13039/501100011033 and by the European Union, ERDF “A way of making Europe”, Fundación Científica AECC (PRYCO223002PEIN, LABAE19027PEIN), the Mission Cancer within HORIZON EU Programme (PANCAID-101096309) and Fundación Ramón Areces. J.G.-A. was supported by Fundación Científica de la Asociación Española Contra el Cáncer (Predoctoral AECC 2021, PRDMA21602GARC). J.M.G.-P. and J.P.R. received funding from the Instituto de Salud Carlos III (ISCIII) through the project grants PI22/00167, PI25/00107 and CIBERONC (CB16/12/00390) and were co-funded by the European Union. J.M.G.-P. and J.P.R. are funded by the Government of the Principality of Asturias through the Agency for Science, Business Competitiveness and Innovation of the Principality of Asturias and co-financed by the European Union (IDE/2024/000778). M.A.-F. was supported by grant CNS2023-1444–73 funded by MCIU/AEI/https://doi.org/10.13039/501100011033 and “EuropeanUnionNextGenerationEU/PRTR” and by the Scientific Foundation of the Spanish Association against Cancer (LABAE235202ALVA). M.E. LL. received funding from the Instituto de Salud Carlos III (ISCIII) through the project grants PI24/00630 and AC24/00057, the latter under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme)., Peer reviewed, Sin experimentacion animal ni uso de NAMs